How to buy Invitrocue shares | A$0.06

Invitrocue Limited is a biotechnology business based in Australia. Invitrocue shares (IVQ) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.06 – the same closing value as a week prior. and has a market cap (total outstanding shares value) of $34.7 million.

How to buy shares in Invitrocue

1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
3. Search for Invitrocue . Find the share by name or ticker symbol: IVQ. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Invitrocue reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At today's price of $0.06, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
6. Check in on your investment. Congratulations, you own a part of Invitrocue . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted Invitrocue 's share price?

Since the stock market crash in March caused by coronavirus, Invitrocue 's share price has had significant positive movement.

Its last market close was $0.06, which is 0.00% up on its pre-crash value of $0.06 and 0.00% up on the lowest point reached during the March crash when the shares fell as low as $0.06.

If you had bought $1,000 worth of Invitrocue shares at the start of February 2020, those shares would have been worth $1,000.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,000.00.

Invitrocue share price

Use our graph to track the performance of IVQ stocks over time.

Invitrocue shares at a glance

• Key figures

Information last updated 2020-10-21.

Latest market close	AUDA$0.06
52-week range	AUDA$0.06 - AUDA$0.06
50-day moving average	AUDA$0.06
200-day moving average	AUDA$0.06
Target price	AUDA$0.47
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	AUDA$-0.007

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

• Brokerage - AU shares: From AUD 5 or 0.05%
• Brokerage - US shares: USD 0
• Sign-up process: Instant
• Support - After hours: Yes

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Invitrocue stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Invitrocue Limited by TradingView

Invitrocue price performance over time

Historical closes compared with the close of A$0.06 on 2020-10-22

1 week (2020-10-23)	0%
1 month (2020-09-30)	0%
3 months (2020-07-30)	0%
6 months (2020-04-30)	0%

1 year (2019-10-30)	0%
2 years (2018-10-26)	N/A
3 years (2017-10-30)	-30.23%
5 years (2015-10-26)	N/A

Invitrocue financials

Gross profit TTM	$252,858
Return on assets TTM	-167.33%
Return on equity TTM	-1214.48%
Profit margin	0%
Book value	0.003
Market capitalisation	$34.7 million

TTM: trailing 12 months

Invitrocue share dividends

We're not expecting Invitrocue to pay a dividend over the next 12 months.

Have Invitrocue 's shares ever split?

Invitrocue 's shares were split on a 1:52 basis on 19 May 2015. So if you had owned 52 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Invitrocue shares – just the quantity. However, indirectly, the new 5100% higher share price could have impacted the market appetite for Invitrocue shares which in turn could have impacted Invitrocue 's share price.

Invitrocue share price volatility

Over the last 12 months, Invitrocue 's shares have ranged in value from as little as $0.06 up to $0.06. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Invitrocue 's is 0.5232. This would suggest that Invitrocue 's shares are less volatile than average (for this exchange).

Invitrocue overview

Invitrocue Limited engages in the research and experimental development on biotechnology, life, and medical science primarily in Singapore, Australia, China, Hong Kong, and Germany. The company develops Onco Patient-Derived Organoid (PDO) test, a personalized cancer treatment for cancer patients; and 3D CelluSponge series, a 3D in-vitro platform technology for various applications, including 3D cell culture, hepatocyte culture, in-vitro drug metabolism and pharmacokinetics assays and toxicology, stem cell differentiation, PDO, and pathogen infection and detection. It also provides respiratory disease, and customized assays and disease modelling services. Invitrocue Limited was founded in 2012 and is headquartered in Singapore.

Frequently asked questions

• What percentage of Invitrocue is owned by insiders?

  Currently 47.886% of Invitrocue shares are held by insiders.

• When does the fiscal year end for Invitrocue ?

  Invitrocue 's fiscal year ends in June.

• Where is Invitrocue based?

  Invitrocue 's address is: 11 Biopolis Way, Singapore, Singapore, 138667

• What is Invitrocue 's ISIN number?

  Invitrocue 's international securities identification number is: AU000000IVQ8